Zheng Quan Shi Bao·2025-08-13 05:51Core Viewpoint - WuXi AppTec (603259) is expected to achieve approximately 20.64% year-on-year revenue growth, reaching about 20.799 billion yuan in the first half of 2025, with a net profit attributable to shareholders expected to increase by approximately 101.92% to about 8.561 billion yuan [1] Group 1: Company Performance - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, expanding new capabilities and production capacity while optimizing production processes and improving operational efficiency [1] - As of the end of 2024, WuXi AppTec has approximately 6,000 active clients, with about 5,500 in its ongoing business, and added around 1,000 new clients throughout the year [2] - The company's backlog for ongoing business reached 49.31 billion yuan, representing a year-on-year increase of 47.0% [2] Group 2: Industry Context - The performance of WuXi AppTec is closely linked to the development of the global pharmaceutical industry and investments in new drug research and development [1] - The global pharmaceutical market is expected to continue growing due to factors such as economic development, population growth, aging demographics, technological advancements, rising healthcare expenditures, and increasing public demand for healthy living [1]